Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

BACKGROUND: Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (EPC) leading to revascularization and renewed growth within the residual tumor....

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Linh, Fifis, Theodora, Christophi, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962549/
https://www.ncbi.nlm.nih.gov/pubmed/27460820
http://dx.doi.org/10.1186/s12885-016-2568-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962549/
https://www.ncbi.nlm.nih.gov/pubmed/27460820
http://dx.doi.org/10.1186/s12885-016-2568-7

Ejemplares similares